J. J. Wyse, PhD, B. J. Morasco, PhD, S. K. Dobscha, MD, M. I. Demidenko, BS, T. H. A. Meath, MPH, and T. I. Lovejoy, PhD, MPH, “Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified”, J of Opioid Management, vol. 14, no. 4, pp. 295–303, Jul. 2018.